Navigation Links
Ardea to Present at Cowen and Company's 28th Annual Health Care Conference
Date:3/11/2008

SAN DIEGO, March 11 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA) today announced that Barry D. Quart, PharmD, President and CEO of Ardea Biosciences, will present at Cowen and Company's 28th Annual Health Care Conference.

Date: Tuesday, March 18, 2008

Time: 4:40 p.m. Eastern Time

Location: The Boston Marriott Copley Place Hotel, Boston, MA

Webcast:

http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=RDEA&item_id=1 779991

About Ardea Biosciences, Inc.

Ardea Biosciences of San Diego, California is a biotechnology company focused on the discovery and development of small-molecule therapeutics in virology, oncology and inflammation. The Company has two product candidates in clinical development and several others in preclinical development. Ardea's most advanced clinical development candidate is RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which is in a Phase 2a study for the treatment of HIV. In addition, the Company is investigating RDEA806 for the treatment of gout. The Company's lead mitogen-activated ERK kinase (MEK) inhibitor, RDEA119, is in a Phase 1 study in advanced cancer patients and is being investigated for the treatment of inflammatory diseases. Ardea also is developing a next-generation NNRTI for HIV and a next-generation MEK inhibitor for both cancer and inflammatory diseases.

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncert
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
2. Ardea Biosciences Announces Changes to Research Management
3. Ardea Biosciences, Inc. Reports Third Quarter 2007 Operating and Financial Results
4. Ardea Biosciences to Participate in RBC Capital Markets 2007 Healthcare Conference
5. Ardea Biosciences Announces $40 Million Private Placement
6. Ardea Biosciences to Present Preclinical Data on Three HIV Non-Nucleoside Reverse Transcriptase Inhibitors During 15th Annual Conference on Retroviruses and Opportunistic Infections
7. Ardea Biosciences Establishes Scientific Advisory Board for HIV Program
8. Ardea Biosciences to Present at Roth Capital Partners 20th Annual OC Growth Stock Conference
9. Ardea Biosciences Establishes Scientific Advisory Board for Inflammation Program
10. Ardea Biosciences to Move Headquarters and R&D Laboratories to San Diego
11. Imagenetix Inc. to Present at Noble Small Cap Financial Conference on August 21, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... DIEGO , Nov. 20, 2014 ... has been dosed in its Phase 1 trial ... cisplatin for the treatment of malignant pleural mesothelioma ... Group is conducting clinical trials on ADI-PEG 20, ... agents, for the treatment of several other indications, ...
(Date:11/21/2014)... NEW YORK and SAN DIEGO ... CYTX ), today announced that President and CEO Marc Hedrick ... 2014. DATE:   Thursday, December 4, 2014 ... LINK:     Click here or paste this URL into ... is recommended that investors pre-register to save time and receive ...
(Date:11/18/2014)... 2014 Cord Blood Registry® (CBR®) announces ... Annual World Stem Cell Summit, the largest global meeting of ... Stem Cell Summit will be held December 3-5 at the ... The World Stem Cell Summit ... and therapies, convening the most prominent figures in the field ...
(Date:11/18/2014)... New Orleans, LA (PRWEB) November 17, 2014 ... developer of build-to-order, open architecture blade-based and rackmount ... new NVIDIA® Tesla® K80 dual-GPU accelerator throughout its ... Utilizing a pair of the company‚Äôs latest proprietary ... up to eight discrete NVIDIA Tesla K80 dual-GPU ...
Breaking Biology Technology:Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus Pemetrexed and Cisplatin in Malignant Pleural Mesothelioma And Non-Squamous Non-Small Cell Lung Carcinoma 2Cytori Therapeutics to Provide Corporate Update and Investor Presentation on December 4 through a Live, Interactive Webcast 2Cytori Therapeutics to Provide Corporate Update and Investor Presentation on December 4 through a Live, Interactive Webcast 3Cytori Therapeutics to Provide Corporate Update and Investor Presentation on December 4 through a Live, Interactive Webcast 4Cord Blood Registry Sponsors 2014 World Stem Cell Summit 2Cord Blood Registry Sponsors 2014 World Stem Cell Summit 3Cirrascale® Expands Multi-GPU Peering Solutions with Support for New NVIDIA Tesla K80 Dual-GPU Accelerators 2Cirrascale® Expands Multi-GPU Peering Solutions with Support for New NVIDIA Tesla K80 Dual-GPU Accelerators 3
... Charter Business , a division of ... develop its partnership with Berbee Information Networks ... Pharmacy Cooperative (IPC) to Berbees data center in ... T1 lines between multiple Telco vendors, Charter hands off ...
... Metavante Corporation and First Data Corporation ... agreement that provides for the purchase of substantially all ... Metavante for approximately $610 million in cash. As the ... approximately $389 million and NYCE will become a Metavante ...
... exposures to agricultural and lawn care pesticides may cause ... noticed, according to a study conducted by ... being published in the May 2004 issue of ... Institute of Environmental Health Sciences, National Institutes of Health. ...
Cached Biology Technology:Charter and Berbee connect Pharmacy Cooperative 2Metavante and First Data to buy PIN-debit company NYCE 2Infertility linked to lawn chemicals by Marshfield Clinic researcher 2
(Date:11/4/2014)... LAKE CITY, Nov. 5, 2014 – University of Utah ... enzymes to help jet fuel produce electricity without needing ... be used to power portable electronics, off-grid power and ... online today in the American Chemical Society journal ... electricity through a chemical reaction between a fuel and ...
(Date:11/4/2014)... , November 4, 2014   ... vertical market growth   Fuel3D , a ... closed a funding round totaling $6.4 million (£4 million). This ... funding secured earlier this year and paves the way for ... 2015. The funding round was led by Chimera ...
(Date:11/3/2014)... 2014  NeuroSigma ® , Inc. (NeuroSigma), a ... focused on commercialization of its non-invasive ... of neurological and neuropsychiatric disorders, announced today that ... a Notice of Allowance for Mexican Patent Application ... NeuroSigma and the Regents of the University of ...
Breaking Biology News(10 mins):Jet-fueled electricity at room temperature 2Fuel3D Secures $6.4 Million in Expansion Funding 2Fuel3D Secures $6.4 Million in Expansion Funding 3NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 2NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 3
... Researchers at Case Western Reserve University have developed a ... to diseased areas within hours, as opposed to the ... , Using laboratory mice, drug delivery time from injection ... to mere hours. Using this as a model for ...
... of Canadian and Finnish scientists has identified a protein able ... involved in the recognition and the elimination of infectious agents. ... Immunology and Cancer (IRIC) at the Universit de Montral in ... in the latest edition of the journal Immunity ...
... at The University of Texas at Austin is part ... that should simplify the water desalination process, increasing access ... "If we make the desalination process more efficient with ... a gallon of water, which will expand the availability ...
Cached Biology News:Cancer drug delivery research at Case Western Reserve University cuts time from days to hours 2Cancer drug delivery research at Case Western Reserve University cuts time from days to hours 3Identification of protein able to stimulate production of T-cells 2New chlorine-tolerant, desalination membrane hopes to boost access to clean water 2
WTAP Antibody...
Anti-Dardarin Immunogen: Synthetic peptide from rat LRRK2. Available Date: 38814...
... MSY2/YBOX2 ( Abpromise for all ... Synthetic peptide derived from within ... Human MSY2/YBOX2. (Note: the amino ... (Peptide available as ab27460 ...
Request Info...
Biology Products: